News
Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...
High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...
Lipoprotein(a) is a type of cholesterol that lurks in the body, undetected by routine tests and undeterred by existing drugs, ...
13d
Clinical Trials Arena on MSNEli Lilly’s lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trialThe Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.
High cholesterol levels may adversely affect your heart health leading to myocardial infarction and other cardiac diseases.
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...
A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results